Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF Therapy Comparing Syringe Preparation Time Using Ranibizumab Vial and Pre-filled Syringe
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 19 Oct 2020 Status changed from active, no longer recruiting to completed.
- 05 Apr 2019 Planned End Date changed from 1 Jun 2019 to 1 Nov 2019.
- 05 Apr 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Nov 2019.